---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-028205"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:19:40.669046+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Insmed prices $650M stock offering of 12.6M shares; net ~$713.9M

## Summary
- Offering of 12,621,359 shares at $51.50/share; net proceeds to Insmed of ~$713.9M (incl. option exercise).
- Underwriters exercised full 30-day option to purchase an additional 1,893,203 shares.
- Proceeds to fund brensocatib R&D and pre-commercialization, ARIKAYCE commercialization, TPIP R&D.
- Goldman Sachs, Leerink Partners, and J.P. Morgan are joint book-running managers; Morgan Stanley, Cantor, Stifel co-lead.
- Offering expected to close May 31, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001140361-24-028205
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124028205/0001140361-24-028205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124028205/ny20029730x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-028205
- JSON: https://secwatch.observer/filing/0001140361-24-028205.json
- Plain text: https://secwatch.observer/filing/0001140361-24-028205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.